David R. Anderson, MD; Michael J. Dunbar, MD; Susan R. Kahn, MD
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2191.
Anderson DR, Dunbar MJ, Kahn SR. Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty. Ann Intern Med. 2013;159:502-503. doi: 10.7326/0003-4819-159-7-201310010-00018
Download citation file:
Published: Ann Intern Med. 2013;159(7):502-503.
We thank Drs. Granziera and Cohen for their comments about our recent EPCAT (Extended Prophylaxis Comparing Low Molecular Weight Heparin to Aspirin in Total Hip Arthroplasty) study, which provides further evidence about the benefit of aspirin for the prevention of VTE after total hip arthroplasty (1). As Drs. Granziera and Cohen point out, patients randomly assigned to receive either low-molecular-weight heparin or aspirin had low rates of major risk factors for VTE and bleeding. More than 90% of the participants had none of the major risk factors cited for thromboembolism, and more than 98% had no history of major bleeding. These risk factors were similarly distributed in the 2 groups of patients.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only